1.Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty.
Yan LIANG ; Hong WEI ; Jian-ling ZHANG ; Ling HOU ; Xiao-ping LUO
Chinese Journal of Pediatrics 2004;42(11):845-849
OBJECTIVEGonadotropin-releasing hormone agonist (GnRHa) is widely used for the treatment of precocious puberty, but there was no identical regime for the dosage and the interval of administration. The aim of this study was to assess the feasibility of subcutaneous administration of Triptorelin with a prolonged interval (six weeks) for the suppression of pituitary-gonadal axis and clinical signs in girls with idiopathic central precocious puberty (ICPP).
METHODSForty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B. There were no significantly differences in chronological age, height, weight, age at clinical onset of puberty and bone age between the two groups before treatment. Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B. Both forms were given for more than 12 months consecutively. During the period of treatment, the clinical parameters including height, weight, pubertal stage, bone age, uterine volume and ovarian size were documented. The serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and estradiol (E(2)) were monitored using immunoenzymometric assay.
RESULTSBoth treatment regimes can completely suppressed the pituitary-gonadal axis. The clinical signs of pubertal development regressed or stabilized in all patients. Breast developments, as reflected by Tanner staging, were regressed. Uterine volume decreased after treatment, however, this decrease did not reach statistical significance. Mean ovarian volume did not change significantly during treatment. The height velocity was significantly decreased from a pretreatment value of 6.3 +/- 1.4 cm/year to 5.8 +/- 1.2 cm/year in group A and 6.7 +/- 1.3 cm/year to 5.4 +/- 1.0 cm/year in group B, respectively. The rate of skeletal maturation was reduced significantly during treatment. The ratio of bone age/chronological age was 1.2 +/- 0.2 or 1.3 +/- 0.3 at the onset of therapy and decreased significantly after the treatment to 0.7 +/- 0.2 or 0.9 +/- 0.1, respectively. The predicted adult height increased significantly and progressively during therapy. The levels of serum LH, FSH and E(2) were returned to the prepubertal condition after 6 - 8 weeks treatment and remained suppressed for the duration of treatment. No significantly side effects of therapy were noted. The most common adverse event during SC treatment was that a non-irritating, 1 cm in diameter mass can be palpated at the site of subcutaneous injection in the abdominal wall of group A patients. It gradually decreased in size, and disappeared after 8 - 12 weeks. Two girls had minimal withdrawal virginal bleeding episodes after the first injection.
CONCLUSIONBoth IM and SC triptorelin administration were clinically effective. They can induce profound suppression of hypothalamic-pituitary-gonadal axis while stabilizing height velocity, slowing bone maturation and increasing predicted adult height. These results suggest that subcutaneous injection of triptorelin in 6 weeks intervals at a dosage of 3.75 mg was a safe and acceptable regime for ICPP with good efficacy.
Body Height ; drug effects ; Breast ; drug effects ; Drug Administration Schedule ; Feasibility Studies ; Female ; Gonadotropin-Releasing Hormone ; administration & dosage ; agonists ; Humans ; Injections, Intramuscular ; Injections, Subcutaneous ; Puberty, Precocious ; drug therapy ; Triptorelin Pamoate ; administration & dosage ; Uterus ; drug effects
2.Ovarian Hyper-Response to Administration of an GnRH-Agonist Without Gonadotropins.
Hyun Tae PARK ; Hyo Sook BAE ; Tak KIM ; Sun Haeng KIM
Journal of Korean Medical Science 2011;26(10):1394-1396
Several case reports have indicated that a small subgroup of patients may develop ovarian hyperstimulation following the administration of gonadotropin-releasing hormone agonists (GnRHa) without gonadotropins. However, since only few such cases have been published, it is unclear what course to follow in subsequent cycles after ovarian hyperstimulation in the first cycle using only GnRHa. A 33-yr-old woman was referred to in vitro fertilization for oocyte donation. A depot preparation (3.75 mg) of tryptorelin without gonadotropins induced ovarian multifollicular enlargement with high estradiol level, and was followed by human chorionic gonadotropin administration and oocyte retrieval. In a subsequent cycle of the same patient, a low dose of tryptorelin (0.05 mg) did not induce ovarian hyperstimulation, and resulted in clinical pregnancy. This report shows potential management of ovarian hyperstimulation following the administration of GnRHa without gonadotropins.
Adult
;
Chorionic Gonadotropin/administration & dosage
;
Female
;
Fertilization in Vitro
;
Gonadotropin-Releasing Hormone/*agonists
;
Humans
;
*Oocyte Donation
;
Oocyte Retrieval
;
Ovarian Hyperstimulation Syndrome/*chemically induced
;
Ovary/*drug effects
;
Ovulation Induction/methods
;
Pregnancy
;
Triptorelin Pamoate/*administration & dosage/adverse effects
3.Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer.
Ning-chen LI ; Yi SONG ; Hao-wen JIANG ; Qiang DING ; Wei-dong GAN ; Hong-qian GUO ; Ze-yu SUN ; Zhi-quan HU ; Zhang-qun YE ; Qiang WEI ; Yan-qun NA
Chinese Journal of Surgery 2008;46(21):1653-1657
OBJECTIVETo evaluate the efficacy and safety of gonadotropin-releasing hormone analogue (GnRHa) triptorelin 11.25 mg 3-month sustained release formulations in the treatment of metastatic prostate cancer.
METHODSFrom January 2004 to March 2006, a randomized, parallel-controlled, multicenter clinical trial was conducted. One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62). Changes from baseline of TPSA, prostate volume, testosterone, LH, FSH, PRL and estradiol were assessed over 3 months. Changes of the metastatic lesions were also observed and evaluated. The occurrences of adverse events were evaluated as well.
RESULTSAfter 3 months treatment, total PSA level decreased significantly from baseline both in 11.25 mg group and 3.75 mg group. At 30, 60 and 90 days, TPSA (median level) declined from 164.55 microg/L into 11.34, 4.12, 3.89 microg/L in 11.25 mg group, and from 101.38 microg/L into 6.88, 2.41, 2.57 microg/L in control group respectively. The patients ratio with over 90% decreasing from TPSA baseline were 78.6% and 75.5% respectively in two groups (P = 0.700). Prostate volume were also decreased significantly in both groups, median volume declined from 48.0 mm(3) into 21.5 mm(3) in 11.25 mg group and from 45.0 mm(3) into 21.0 mm(3) in 3.75 mg group. No significant differences were found between the two groups in changes of TPSA (P = 0.601) and prostate volume (P > 0.05). Both formulations were able to induce castration levels, 0.31 microg/L in 11.25 mg group and 0.26 microg/L in 3.75 mg group (P > 0.05). 13.8% and 17.7% of adverse events were recorded respectively in two groups, and no differences were found (P = 0.547).
CONCLUSIONAs a new long-acting sustained release formulation, triptorelin 11.25 mg is comparable to triptorelin 3.75 mg formulation in the aspect of efficacy and safety for the treatments of metastatic prostate cancer.
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal ; administration & dosage ; therapeutic use ; Gonadotropin-Releasing Hormone ; analogs & derivatives ; therapeutic use ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms ; drug therapy ; pathology ; Safety ; Treatment Outcome ; Triptorelin Pamoate ; administration & dosage ; therapeutic use
4.Effect of low-dose triptorelin on pituitary down-regulation for patients undergoing in vitro fertilization and embryo transfer.
Wen-Jie ZHU ; Xue-Mei LI ; Xiu-Ming CHEN ; Li ZHANG
National Journal of Andrology 2003;9(5):367-369
OBJECTIVETo observe the effect of low-dose triptorelin in later luteal phase on pituitary down-regulation for patients undergoing IVF-ET.
METHODSOne hundred and twenty patients were randomly divided into 2 groups(A and B). In group A, the patients were treated with triptorelin of 0.1 mg subcutaneously daily started on day 21 of menstrual cycle for 7 days. In group B, the patients were treated with long protocol of Buserelin intranasal spray. Comparisons were made between the groups in serum concentrations of FSH, LH, E2, T, PRL and P on the third day (D3) of superovulation cycle and on the day of hCG administration, highly purified follicle-stimulating hormone (HP) dosages, and so on.
RESULTSIn group A, mean serum LH level on D3 and the day of hCG was (1.55 +/- 0.99) U/L and (2.70 +/- 1.45) U/L, E2 was (85.66 +/- 13.13) pmol/L and (5,451.31 +/- 1,900.61) pmol/L, respectively, significantly lower than those of group B (P < 0.001; P < 0.01; P < 0.05; P < 0.001). Mean HP(75 IU/Amp) dosage per treatment cycle in group A was 28.20 +/- 11.03 ampoules, significantly higher than 22.30 +/- 6.40 ampoules in group B(P < 0.001).
CONCLUSIONSLow-dose triptorelin in later luteal phase is effective for down-regulation of pituitary and produces more suppression on endogenous LH in pituitary than Buserelin long protocol.
Adult ; Down-Regulation ; Embryo Transfer ; Estradiol ; blood ; Female ; Fertilization in Vitro ; Humans ; Injections, Subcutaneous ; Luteinizing Hormone ; blood ; Luteolytic Agents ; administration & dosage ; Pituitary Gland ; drug effects ; physiology ; Triptorelin Pamoate ; administration & dosage
5.Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
Xin CHEN ; Shu-xian FENG ; Ping-ping GUO ; Yu-xia HE ; Yu-dong LIU ; De-sheng YE ; Shi-ling CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(2):215-220
The effects of pituitary suppression with one-third depot of long-acting gonadotropin-releasing hormone (GnRH) agonist in GnRH agonist long protocol for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) were investigated. A retrospective cohort study was performed on 3186 cycles undergoing IVF/ICSI with GnRH agonist long protocol in a university-affiliated infertility center. The pituitary was suppressed with depot triptorelin of 1.25 mg or 1.875 mg. There was no significant difference in live birth rate between 1.25 mg triptorelin group and 1.875 mg triptorelin group (41.2% vs. 43.7%). The mean luteinizing hormone (LH) level on follicle-stimulating hormone (FSH) starting day was significantly higher in 1.25 mg triptorelin group. The mean LH level on the day of human chorionic gonadotrophin (hCG) administration was slightly but statistically higher in 1.25 mg triptorelin group. There was no significant difference in the total FSH dose between the two groups. The number of retrieved oocytes was slightly but statistically less in 1.25 mg triptorelin group than in 1.875 mg triptorelin group (12.90±5.82 vs. 13.52±6.97). There was no significant difference in clinical pregnancy rate between the two groups (50.5% vs. 54.5%). It was suggested that one-third depot triptorelin can achieve satisfactory pituitary suppression and produce good live birth rates in a long protocol for IVF/ICSI.
Adult
;
Down-Regulation
;
Female
;
Fertilization in Vitro
;
methods
;
Follicle Stimulating Hormone
;
blood
;
Humans
;
Live Birth
;
Luteinizing Hormone
;
blood
;
Pituitary Gland
;
drug effects
;
secretion
;
Pregnancy
;
Sperm Injections, Intracytoplasmic
;
methods
;
Triptorelin Pamoate
;
administration & dosage
;
pharmacology
;
therapeutic use